LIVNLivaNova PLC
$76.39+39% 1Y
$76.39
$49.5752 weeks$85.43
The financials
LivaNova PLC by the numbers
LivaNova PLC (LIVN) reported revenue of $391M in Q2 2026 (quarter ended Jun 30, 2026), up 11% from the same quarter a year earlier. That came with a gross margin of 70% and net income of $109M (28% of revenue). For the full year FY2025, revenue was $1.39B (+11% year on year) and net income −$242M. Its largest segment in Q2 2026 was Neuromodulation at $127M, 63% of the disclosed total, well ahead of Cardiopulmonary at 37%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $391M | $353M | +11% |
| Gross profit | $274M | $239M | +15% |
| Operating income | $49M | $54M | −8.7% |
| Net income | $109M | $27M | +300% |
| Diluted EPS | $1.93 | $0.50 | +286% |
| Operating | Revenue | Share |
|---|---|---|
| Neuromodulation | $127M | 63% |
| Cardiopulmonary | $73M | 37% |
Business segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Jun 2026Total $199.3M (+7.9%)
Neuromodulation grew +8.0% year on yearCardiopulmonary +2.2% year on year
Segment Latestquarter on quarteryear on year
- Neuromodulation$126.6M$126.6Mquarter on quarter +9.7%year on year +8.0%+9.7%+8.0%
- Cardiopulmonary$72.8M$72.8Mquarter on quarter +5.1%year on year +2.2%+5.1%+2.2%